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Abstract: This review summarizes several scientific contributions at the recent Satellite 
Symposium of the European Society of Hypertension, held in Milan, Italy. Arterial stiffen-
ing and its hemodynamic consequences can be easily and reliably measured using a range of 
noninvasive techniques. However, like blood pressure (BP) measurements, arterial stiffness 
should be measured carefully under standardized patient conditions. Carotid-femoral pulse 
wave velocity has been proposed as the gold standard for arterial stiffness measurement and is 
a well recognized predictor of adverse cardiovascular outcome. Systolic BP and pulse pressure 
in the ascending aorta may be lower than pressures measured in the upper limb, especially in 
young individuals. A number of studies suggest closer correlation of end-organ damage with 
central BP than with peripheral BP, and central BP may provide additional prognostic informa-
tion regarding cardiovascular risk. Moreover, BP-lowering drugs can have differential effects 
on central aortic pressures and hemodynamics compared with brachial BP. This may explain 
the greater beneficial effect provided by newer antihypertensive drugs beyond peripheral BP 
reduction. Although many methodological problems still hinder the wide clinical application 
of parameters of arterial stiffness, these will likely contribute to cardiovascular assessment and 
management in future clinical practice. Each of the abovementioned parameters reflects a dif-
ferent characteristic of the atherosclerotic process, involving functional and/or morphological 
changes in the vessel wall. Therefore, acquiring simultaneous measurements of different param-
eters of vascular function and structure could theoretically enhance the power to improve risk 
stratification. Continuous technological effort is necessary to refine our methods of investigation 
in order to detect early arterial abnormalities. Arterial stiffness and its consequences represent 
the great challenge of the twenty-first century for affluent countries, and “de-stiffening” will 
be the goal of the next decades.
Keywords: arterial elasticity, stiffness, compliance, central blood pressure, pulse wave 
velocity
Introduction
Interpretation of the arterial pulse has been an important part of the medical examina-
tion from ancient times. The arterial pulse was familiar to Chinese, Indian, Greek, and 
Roman physicians who exploited it regularly in the diagnosis of disease. Galen, a Greek 
doctor who lived in the second century BC, wrote a book entitled “On Prognosis from 
the Pulse” in which he described 27 varieties of pulses. Modern understanding of the 
cardiovascular system and systematic study of the pulse started in the sixteenth century 
when Józef Strus´, a Polish scholar and humanist, published the book “ Sphygmicae artis 
iam mille ducentos annos perditae et desideratae Libri V.” Józef Strus´ was born in 1510 in 
Poznan´, started his studies in the Faculty of Philosophy at Jagiellonian University in 
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Cracow, and then studied at the College of Medicine and 
Philosophy in Padua from 1532 to 1537. In the second half of 
1537, Józef Strus´ returned to Cracow University. Renaissance 
medicine, similar to medieval medicine, was based on the 
teachings of Galen. The impressive and logically structured 
medical knowledge in Galen’s works (albeit containing many 
errors) brought the less critical medieval minds to the belief 
that whatever Galen had said was indisputable and could 
not be questioned. Strus´ emphasized the practical benefits 
derived from measuring a patient’s pulse. In his masterpiece 
published in Basel in 1555, Józef Strus´ discussed the types 
of pulse and their clinical significance. The large number of 
pulse types described in his book reflects the better powers of 
observation by doctors of that time, which has been replaced 
today by instruments. Despite the fact that Strus´ attached 
great importance to pulse analysis as a diagnostic method, 
on numerous occasions he warned against relying solely 
on it for diagnosis, emphasizing the need for an inquisitive 
medical interview and a thorough examination of the patient. 
A rational approach to all the medical problems he dealt with 
enabled him to record a pulse using curves analogous to those 
recorded today using a sphygmograph.1 True graphic methods 
for pulse wave recording were introduced much later in the 
nineteenth century by Marey in Paris and by Mahomed in 
London.2 The velocity waveforms they presented look sur-
prisingly similar, given the relative crudity of the methods 
employed, to the waveforms obtained by the most modern 
technology. It is the studies by Strus´ and many other out-
standing scholars who followed in his footsteps that made it 
possible to start the modern era of arterial mechanics.
Arterial stiffness and its hemodynamic consequences 
are now established as predictors of adverse cardiovascular 
outcome. Arterial stiffness is positively associated with sys-
tolic hypertension, coronary artery disease, stroke, and heart 
failure, which are the leading causes of mortality in developed 
countries. Several measures of arterial stiffness have been 
employed, which proved useful as predictors of disease in 
longitudinal studies3–22 (Table 1). Among these, pulse wave 
velocity (PWV) is the parameter which has gained the most 
attention, and its predictive accuracy has been demonstrated 
in a number of studies.3–11,21
Assessment of pulse wave velocity
There are two major wall properties of the artery as a whole, 
ie, arterial stiffness and compliance. These properties depend 
on both arterial structural organization and intrinsic wall 
properties, ie, the elastic modulus. Arterial compliance is 
defined as the change in arterial volume per unit of  pressure 
and reflects the buffering capacity of the arterial wall. Arterial 
distensibility, the inverse of arterial stiffness, is defined as 
the relative change in volume per unit of pressure. Arterial 
compliance depends on arterial stiffness and arterial volume 
(diameter of the vessel) and is determined by different factors, 
the three major determinants being mean arterial pressure 
(MAP), age, and gender. Arterial stiffness increases from 
the central aorta to the peripheral arteries.23 In addition, 
only these elastic arteries, and not muscular arteries, have 
been shown to be predictive of cardiovascular morbidity and 
mortality.23,24 Several noninvasive methods are currently used 
to assess vascular stiffness. PWV and the augmentation index 
(AI) are the two major noninvasive methods of assessing arte-
rial stiffness. Because some studies suggest that the predictive 
value of aortic stiffness may be slightly better than carotid 
artery stiffness, and because of the ease of measurement, 
aortic (carotid-femoral) PWV has been proposed as the gold 
standard for arterial stiffness measurement.23–25
Like blood pressure (BP) measurements, arterial stiffness 
should be measured under standardized patient conditions.26 
It should be performed after at least 10 minutes of supine 
rest in a quiet room with stable room temperature. No meals, 
caffeine, or smoking are allowed for 3 hours beforehand, and 
talking is not allowed during the measurements. Because 
respiration can be of influence, measurements should be the 
average of all cardiac cycles within at least one respiratory 
cycle.26 As for BP measurements, one should also be aware 
of possible white coat effects and diurnal variations in 
arterial stiffness. To limit variability from the latter, repeated 
measures done at the same time of the day are advised. 
Aortic PWV is calculated by dividing the distance trav-
elled by the time travelled. The large majority of devices 
accurately measure time travelled directly by measuring 
the time  difference between the arrival of the pulse wave at 
the femoral and carotid arteries, or indirectly by subtracting 
time from the top of the R wave of the electrocardiogram to 
arrival of the pulse wave at the femoral artery minus time 
from the top of the R wave of the electrocardiogram to pulse 
wave arrival at the carotid artery. The distance travelled 
is estimated mainly by tape measure. Different distance 
estimates have been proposed. The two most frequently used 
are the direct distance from the carotid to femoral artery and 
the subtracted distance, subtracting the distance between the 
sternal notch to the carotid artery from the sternal notch to 
the femoral artery. Conversion equations between these two 
distances have been proposed.27 A recent study comparing 
these tape measure distances with the travelled length 
measured with magnetic resonance imaging showed that 
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Table 1 Studies reporting independent associations between parameters of arterial stiffness and outcome variables
Principal  
investigator
Predictor Clinical setting (n) Age (years) Outcome variables Relative risk (95% CI)
Blacher et al3 PwV eSRD (241) 51 CV mortality 
All-cause mortality
OR 5.9 (95% Ci, 2.3–15.5)a 
OR 5.4 (95% Ci, 2.4–11.9)a
Laurent et al4 PwV HTs (1980) 50 CV mortality 
All-cause mortality
OR 1.51 (95% Ci, 1.08–2.11) 
OR 1.34 (95% Ci, 1.04–1.74)
Meaume et al5 PwV elderly .70 years (141) 87 CV mortality OR 1.19 (95% Ci, 1.03–1.37)
Shoji et al6 PwV eSDR (265) 55 CV mortality 
All-cause mortality
HR 1.18 (95% Ci, 1.00–1.39)b 
HR 1.16 (95% Ci, 1.03–1.29)b
Boutouyrie  
et al7
PwV HTs (1045) 51 CHD 
All CV events
HR 2.66 (95% Ci, 1.27–5.56)b 
HR 1.49 (95% Ci, 0.82–2.71)b
Laurent et al8 PwV HTs (1715) 51 Fatal stroke OR 1.39 (95% Ci, 1.08–1.72)b
Shokawa et al9 PwV Hawaii-Los Angeles- 
Hiroshima study (492)
64 CV mortality 
All-cause mortality
HR 4.24 (95% Ci, 1.39–12.96)c 
HR 1.42 (95% Ci, 0.96–2.11)c,d
willum-Hansen  
et al10
PwV General population,  
MONiCA study (1678)
55 Composite CVeP 
CV mortality 
CHD
HR 1.17 (95% Ci, 1.04–1.32) 
HR 1.20 (95% Ci, 1.01–1.41) 
HR 1.16 (95% Ci, 1.00–1.35)
inoue et al11 PwV Middle-aged and elderly  
Japanese men (3960)
61 All-cause mortality OR 1.28 (95% Ci, 0.97–1.68)e
Mitchell et al21 PwV Framingham Heart  
Study (2232)
63 CV events HR 1.48 (95% Ci, 1.16–1.91)c
London et al12 Ai eSRD (180) 54 All-cause mortality 
CV mortality
HR 1.51 (95% Ci, 1.23–1.86) 
HR 1.48 (95% Ci, 1.16–1.90)
williams et al20 Central PP HTs, ASCOT study (2073) 63 CV events and  
procedures, Ri
HR 1.13 (95% Ci, 1.00–1.26)b
Roman et al14 Central PP American indians Strong  
Heart Study (2403)
64 Fatal and nonfatal  
CV events
HR 1.15 (95% Ci, 1.07–1.24)
Pini et al15 Carotid PP General population $65  
years (398)
73 CV events HR 1.23 (95% Ci, 1.10–1.37)e
wang et al19 Central PP NTs, untreated HTs (1272) 52 CV mortality HR 1.26 (95% Ci, 1.02–1.56)
Roman et al14 Central SBP American indians Strong  
Heart Study (2403)
64 Fatal and nonfatal  
CV events
HR 1.07 (95% Ci, 1.01–1.14)
Jankowski et al17 Aortic PP Patients undergoing  
coronary angiography (1109)
57 Fatal and nonfatal  
CV events
HR 1.25 (95% Ci, 1.09 to 1.43)
wang et al19 Central SBP NTs, untreated HTs (1272) 52 CV mortality HR 1.30 (95% Ci, 1.21–1.51)
Pini et al15 Carotid SBP General population $65  
years (398)
73 CV events HR 1.19 (95% Ci, 1.08–1.31)c
Saladini et al22 Central SBP Young untreated HTs,  
HARVeST study (354)
32 Development of HT  
needing treatment
OR 7.0 (95% Ci, 1.5–33.3)f
Grey et al16 Small artery  
compliance
Outpatients (419) .19 CV events OR 1.50 (95% Ci, 1.20–1.80)
Notes: aAdjusted also for peripheral diastolic blood pressure; badjusted also for peripheral blood pressure; cadjusted also for peripheral systolic blood pressure; dP = 0.08; 
eadjusted also for peripheral pulse pressure; fadjusted also for 24-hour blood pressure.
Abbreviations: PwV, pulse wave velocity; PP, pulse pressure; Ai, augmentation index; SBP, systolic blood pressure; eSRD, end-stage renal disease; HTs, hypertensive 
patients; CV, cardiovascular; CVeP, cardiovascular end point; NTs, normotensive subjects; Ri, renal impairment; Mi, myocardial infarction; CHD, coronary heart disease; 
SD, sudden death; CHF, congestive heart failure; CI, confidence interval; OR, odds ratio; HR, hazard ratio; MONICA, Monitoring of Trends and Determinants in Cardiovascular 
Disease.
the subtracted distance  underestimates the travelled length, 
while using the direct distance, the travelled length is over-
estimated by 25%.28 This study also showed that 80% of the 
direct tape measure distance (80% DD) is a fairly accurate 
estimate of the real travelled distance. Because the European 
Society of Hypertension guidelines propose an aortic stiff-
ness cutoff value of 12 m/sec based on PWV data from direct 
tape measure distances, using the more accurate 80% DD, 
the cutoff value should be adapted accordingly to 9.6 m/sec. 
When using the subtracted distance as in the Framingham 
study, the cutoff value should be 8.4 m/sec. The Framingham 
study showed that using this cutoff value, the probability of 
a first major cardiovascular event within the next 8 years 
was about 3%.24 In the year 2010, reference values for aortic 
stiffness have been published based on the 80% DD. These 
reference value tables also show the range from the 10th to 
the 90th percentile.29 This may allow investigation of whether 
a patient deviating from their percentile over time may be 
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at higher risk and is likely to identify patients at risk much 
earlier. It should be noted that AI and augmentation pressure 
are not surrogates of arterial stiffness. Many devices claim 
to measure arterial stiffness. Some measure PWV of an arte-
rial segment in mixed elastic and muscular arteries, thereby 
weakening their predictive value. Others use methods other 
than PWV and frequently are substantially confounded by 
other factors.
Central BP
In young subjects with elastic arterial walls, systolic BP and 
pulse pressure (PP) in the ascending aorta may be lower 
than BP measured in the upper limb by up to 20 mmHg 
(Figure 1). On average, this difference is lower in the general 
population, and in patients with hypertension approximates 
6–11 mmHg.30 The difference between central and peripheral 
pressure applies to the pulsatile component of BP, whereas 
the steady component (usually represented by MAP) does not 
change significantly along the arterial tree when the subject 
is in the recumbent position.31
Central systolic BP and PP have been shown to be cor-
related with the extent of coronary atherosclerosis, carotid 
intima-media thickness, left ventricular hypertrophy, 
and left ventricular diastolic function.32–34 In addition, a 
number of studies suggest closer correlation of end-organ 
damage with central BP than with peripheral BP.14,19,33 The 
 correlation between PP and coronary atherosclerosis is 
particularly important because most cardiovascular deaths 
are caused by coronary events. Although there is no doubt 
about the presence of a significant relationship between 
the pulsatile BP component and coronary atherosclerosis, 
this link is in fact bidirectional.31 On the one hand, diffuse 
atherosclerotic plaques impair the elastic properties of the 
arterial wall (although unstable, soft, and lipid-rich plaques 
do not impair arterial compliance), while on the other hand, 
increased stiffness enhances the pulsatile component of BP, 
leading to progression of atherosclerotic lesions. This leads to 
a vicious circle, which is difficult to prevent or break in clini-
cal  practice. Several studies have highlighted the predictive 
value of central BP (Table 1). In 1109 subjects followed for 
4.5 years, a 10 mmHg aortic PP increase was associated with 
a 13% increase in cardiovascular events.17 In addition, the 
pulsatile component of BP was at least as good a predictor 
of future cardiovascular events as left ventricular ejection 
fraction, the extent of coronary atherosclerosis, diabetes, and 
kidney function. A recent meta-analysis of five prospective 
studies showed a higher (with borderline significance) 
predictive value of central as compared with peripheral PP, 
although central and peripheral PP were not measured simul-
taneously under the same conditions in all studies included 
in the analysis.18 Accordingly, Wang et al showed that when 
central and peripheral systolic pressure were both included 
60
0 1
m
m
H
g
m
m
H
g
Time (s)
0 1
Time (s)
Radial
Young
Old
Aortic
0 1
Time (s)
0 1
cPP
cPP
cSBP
cSBP
cDBP
cDBP
Incident PW
Incident PW
AP
AP
Time (s)
130
60
130
60
m
m
H
g
m
m
H
g
130
60
130
Figure 1 Radial (left) and aortic (right) waveforms in a young and an old subject.
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into a  regression model, only central pressure remained 
significantly related to cardiovascular risk.19
Moreover, BP-lowering drugs can have differential 
effects on central aortic pressures and hemodynamics com-
pared with brachial BP. According to results from the CAFÉ 
(Conduit Artery Function Evaluation) study, there is evi-
dence that brachial BP is not a good surrogate for the effect 
of antihypertensive drugs on central arterial hemodynamics. 
In CAFÉ, despite a similar effect on brachial systolic BP 
between treatment groups, atenolol-thiazide-based treatment 
was much less effective than amlodipine-perindopril-based 
treatment in lowering central aortic pressures.20 Treatment-
related differences in central aortic pressures may be a 
potential mechanism to explain the different clinical out-
comes between the two treatment arms found in ASCOT (the 
Anglo  Scandinavian Cardiac Outcomes Trial).34 At variance 
with these results, Mitchell et al did not find a significant 
association between central PP and cardiovascular risk.24 
These discordant results may be caused by the difference 
in the  studied populations or methods used for central BP 
assessment. Mitchell et al used applanation tonometry of 
the brachial artery which was criticized on the basis of the 
difficulties with applanation of the brachial artery against 
bone or ligaments, as can be done with the radial and carotid 
arteries.35 It is also argued that the signal is sensed through 
the stiff bicipital aponeurosis when applanation tonometry 
of the brachial artery is used.35 Another study suggested no 
predictive value of central BP and a high predictive value 
of peripheral pressure for cardiovascular events in several 
 hundred elderly female hypertensives.36 It is well known that 
the difference between central and peripheral BP values is 
lower in females than in males and is decreasing with age.37 
Thus, brachial systolic BP becomes a better surrogate of 
central systolic BP in older age groups, chiefly in female 
 individuals, and this could at least partly explain these nega-
tive results. In addition, due to the low prevalence (7%) of 
known vascular disease in the Dart et al hypertensive cohort, 
it is possible that other factors, including hypertension, 
were more relevant in determining outcome than vascular 
stiffness.36
Relationship between central BP 
and age
Only a few population studies have described age-related 
changes in both peripheral and central systolic pressures 
and in pressure amplification. Age-related changes in cen-
tral BP parameters were assessed in randomly recruited 
 European subjects from FLEMENGHO (the Flemish Study 
on Environment, Genes and Health Outcomes, n = 949) and 
EPOGH (the European Project On Genes In Hypertension, 
n = 858).38 Participants on antihypertensive treatment were 
excluded, leaving 1420 subjects for cross-sectional analysis 
of baseline data. For the longitudinal analyses, 398 subjects 
were available with a median follow-up of 4.8 years. PWV 
was obtained from applanation tonometry at the radial artery 
using a SphygmoCor® device. Central systolic BP was 
the maximum pressure of the central waveform.  Systolic 
augmentation was calculated by subtracting the first peak 
shoulder from systolic BP. Pressure amplification was defined 
as peripheral minus central systolic BP. In line with several 
previously published cross-sectional population studies, 
cross-sectional analyses showed that both peripheral and 
central systolic BP increased significantly with age, and 
with steeper slopes in women than in men. The age-related 
increase in central systolic BP assessed cross-sectionally 
was larger than that in peripheral systolic BP in both women 
and men. The pressure amplification decreased with age to 
the same extent in both genders. The slopes of peripheral 
and central systolic augmentation pressure were steeper 
in women than in men. Moreover, in women (,20 years 
versus 40–50 years) as well as in men (30–40 years versus 
60–70 years), central systolic augmentation occurred at 
a younger age than peripheral systolic augmentation. In 
the longitudinal analyses in the subsample of 208 women 
and 190 men, all changes in peripheral and central systolic 
BP were significant from baseline to follow-up. However, 
women had a greater pressure amplification than men. The 
slopes on age for the peripheral and central pressures were 
similar at baseline and follow-up. Age-related increases in 
peripheral and central systolic BP were consistently greater 
in the longitudinal as compared with cross-sectional assess-
ment. Recently, Bia et al studied age-related structural 
and functional vascular parameter profiles in 388 healthy 
 Uruguayan subjects.39 In this sample, they found the expected 
age-related changes in systolic and diastolic pressure for both 
central (aortic) and peripheral (radial) pressure levels, with 
a decrease in the centre-periphery systolic  amplification. 
Both central and peripheral systolic pressure variations 
showed a steeper increase beyond the sixth decade of life. In 
agreement with previous work, beyond that age, the center-
periphery systolic amplification remained constant.40 PWV 
in this population showed a 0.12 m/sec increase per year that 
was comparable with that found by other authors in nonhy-
pertensive subjects.29 Echo Doppler analysis of the carotid 
arteries showed an age-related increase in intima-media 
thickness in both the left and right common carotid arteries 
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of 0.008 mm/year beyond the third decade of life, and an 
increase in both the systolic and diastolic vascular diameters 
with a parallel reduction of circumferential stress with age. 
The data from the above studies indicate that peripheral 
systolic pressure approximates central pressure with aging 
(Figure 1). This might explain why peripheral systolic BP 
becomes the main predictor of cardiovascular complications 
in older subjects.
Central BP and systolic  
hypertension in the young
A controversial issue still debated in the literature is the 
pathogenesis and clinical significance of isolated systolic 
hypertension (ISH) in young subjects. Two main hypoth-
eses have been forwarded to explain ISH in the young. 
 According to McEniery et al, ISH in young subjects may 
be caused by increased stroke volume, early aortic stiffness, 
or by a combination of these two mechanisms.41 At vari-
ance with this hypothesis, some authors claim that ISH in 
youth is “spurious hypertension,” a benign condition due to 
 exaggerated PP amplification at peripheral sites while cen-
tral BP is normal.42,43 In HARVEST (the Hypertension and 
Ambulatory Recording VEnetia STudy), 64 subjects with 
ISH were examined and compared with 287 subjects with 
systolic-diastolic hypertension, and with 34 normotensive 
subjects.22 ISH subjects were divided into two subgroups 
according to whether central systolic BP was below or above 
the median in the group (120.5 mmHg). Arterial compliance 
was impaired in ISH subjects with high central BP, while 
in ISH subjects with low central BP it was similar to that in 
normotensives. In addition, total peripheral resistance was 
increased in ISH subjects with high central systolic BP, 
and was normal in those with low central pressure. During 
a median follow-up of 9.5 years, hypertension requiring 
treatment was developed by 60% of subjects with systolic-
diastolic hypertension (P = 0.022 versus normotensives) 
and by 50% of ISH subjects with high central systolic BP 
(P = 0.041 versus normotensives), while in ISH subjects 
with low central pressure, the rate of hypertension was 
similar to that observed in normotensives (15.1% and 14.7%, 
respectively),22 as shown in Figure 2.
A limitation to the applicability of central BP assessment 
in clinical practice may be the lack of normal limits in 
young-to-middle-aged individuals, because of the paucity 
of longitudinal data in this segment of the population. 
Hulsen et al43 used the 90th percentile score in 750 
adults aged 26–31 years to define the maximum allowed 
central systolic BP. Using this approach, spurious systolic 
 hypertension in individuals with ISH was defined as a cen-
tral systolic BP less than 124 mmHg for men and less than 
120 mmHg for women. In a smaller study performed in normo-
tensive  individuals, O’Rourke et al43 identified the 126 mmHg 
level as the upper normal limit for central systolic BP. Based 
on the results from HARVEST, 120 mmHg may be regarded 
as the approximate threshold value for identifying ISH indi-
viduals with true normal central systolic BP, because below 
this partition value, the risk of hypertension was shown to 
be close to that of normotensive individuals.22 According to 
the HARVEST results, the 125 mmHg cutoff level may be 
used to identify truly hypertensive patients.22
Methodological issues
Although central BP has achieved much attention in recent 
years for the assessment of cardiovascular risk, it should be 
pointed out that there are still methodological problems with 
its non invasive measurement. This is attested to by the results 
of a recent study that demonstrated considerable differences 
between central pressure estimates obtained with the Omron® 
and the SphygmoCor device, due to algorithm differences.44 
Central systolic BP estimates obtained with the two devices 
correlated strongly (r = 0.99), but the Omron estimate was 
18.8 mmHg higher than the SphygmoCor estimate.
Central BP measured invasively cannot be used in 
everyday clinical practice and we must rely on  noninvasive 
0
NT ISH low
P = ns P = 0.041
19.1 14.8
P = 0.022
ISH high SDH
1
2
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6
Figure 2 Odds ratios and confidence intervals for development of hypertension 
needing antihypertensive treatment from a multivariable logistic regression.
Notes: Odds ratios represent risk of hypertension for the three groups of 
hypertensive versus normotensive subjects; P values are adjusted for age, gender, 
body mass index, parental hypertension, physical activity, smoking, coffee, alcohol, 
body mass index change, follow-up duration, average 24-hour systolic blood 
pressure, diastolic blood pressure, and heart rate. Data from Saladini et al.22
Abbreviations: NT, normotensives; iSH low, isolated systolic hypertensives with 
low central systolic blood pressure; iSH high, isolated systolic hypertensives with 
high central systolic blood pressure; SDH, systolic-diastolic hypertensives. 
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Table 2 Noninvasive methods of central blood pressure measurement
Method Device Principle Sources of errors
Applanation tonometry  
of radial artery
eg, SphygmoCor® Central systolic pressure is calculated  
using transfer function from calibrated  
radial pulse
Noninvasive measurement of brachial BP* 
Calibration of radial pulse with brachial  
pressure
Applanation tonometry  
of carotid artery
eg, Complior®,  
SphygmoCor
Carotid pulse wave is calibrated  
with brachial pressure
Noninvasive measurement of brachial BP* 
Difference between diastolic and mean  
pressure in carotid and brachial artery 
Difference between BP in carotid artery  
and ascending aorta
Oscillometric method eg, arteriograph,  
BPLabVasotens®
Calculation of central systolic pressure  
is based on late systolic wave amplitude 
Calibration of brachial pressure wave  
with brachial pressure
Noninvasive measurement of brachial BP*
Secondary systolic wave  
in radial pulse
eg, SphygmoCor,  
Omron HeM-9000®
Second systolic peak in applanated  
radial pulse approximate central  
systolic pressure
Noninvasive measurement of brachial BP* 
Calibration of radial pulse with brachial  
pressure
N-point moving average  
method
BPro® Moving average acts as a low pass filter Noninvasive measurement of brachial BP*
Note: *when the radial arterial pulses are calibrated with brachial cuff pressures, calibration errors are transferred to the predicted values.
Abbreviation: BP, blood pressure.
techniques. There are five methods that hold promise 
for noninvasive central BP determination (Table 2), ie, 
applanation tonometry of the radial artery, applanation 
tonometry of the carotid artery, the secondary systolic wave 
method, oscillometric method, and the N-point moving 
average method. The N-point moving average method, as 
well as the oscillometric method, allows for 24-hour central 
systolic pressure monitoring.45 One should be aware that 
using any of the above methods, the predicted central BP 
values are distorted by the error related to noninvasive 
measurement of brachial BP.46 Recently, the use of diameter 
distension waveforms instead of applanation tonometry 
was also suggested.47
Taking into account all the available evidence, it seems 
too early to recommend replacement of peripheral BP with 
central BP measurement in everyday clinical practice. Before 
such a recommendation can be made, several conditions 
should be fulfilled, ie: the high accuracy and reliability of 
central pressure measurements should be shown beyond any 
doubt; the higher predictive value of central pressure for 
cardiovascular events as compared with peripheral pressure 
should be proved in various patient subsets; the measurement 
of central pressure should be inexpensive, easy, and not 
time-consuming; and central BP should be a better surrogate 
for the effect of antihypertensive drugs on cardiovascular 
outcomes compared with peripheral BP. For the time being, 
central BP measurement and assessment of arterial stiffness 
and compliance parameters can be considered useful adjuncts 
to clinic and ambulatory brachial BP measurements for better 
assessment of cardiovascular risk.
Clinical significance of arterial 
distensibility in young to  
middle-aged subjects
The association of age with various arterial distensibility 
parameters has been described extensively in the literature. 
However, little is known about the clinical significance 
of arterial distensibility assessment in young subjects. 
O’Rourke et al observed a progressive increase in carotid-
femoral PWV with aging, that started in childhood, while no 
association with age was found for the muscular upper limb 
arteries.43 In a cross-sectional study involving the general 
population, Janner et al reported a curvilinear increase in AI 
with age, that had already started at the age of 20 years.48 For 
large artery (C1) and small artery (C2) compliance, assessed 
with the HDI device, in a population of healthy normotensive 
subjects of normal weight, Gardner and Parker observed a 
progressive increase in compliance with aging, in both the 
large and small arteries, until the age of 20–25 years, and 
then a progressive decline.49 In HARVEST, arterial disten-
sibility assessment was performed in a sample of subjects 
aged 20–55 years.50 In this study, a progressive decline in 
C1 and C2 starting from the age of 20 years was seen, with 
a negative correlation that was stronger for C2 (r = −0.41, 
P = 0.001) than for C1 (r = −0.13, P = 0.03). Measures of 
arterial stiffness also showed a progressive increase with age. 
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The correlation was stronger for AI (r = 0.46 P , 0.001) 
than for PWV (r = 0.26 P , 0.001). HARVEST showed that 
arterial distensibility may already be impaired in the early 
stage of  hypertension.50 Compared with a group of normo-
tensive subjects used as controls, hypertensive participants 
showed a lower C1 (14.6 ± 4.6 mL/mmHg × 10 in the latter 
and 17.0 ± 4.7 mL/mmHg × 10 in the former, P = 0.002, 
adjusted for age, gender, height, and heart rate) and 
C2 (6.6 ± 2.8 mL/mmHg × 100 and 8.0 ± 3.8 mL/mmHg × 100, 
respectively, P , 0.001). The hypertensive participants 
also showed a higher PWV (9.0 ± 3.1 m/sec versus 
7.9 ± 1.3 m/sec), even if the difference did not reach the level 
of statistical significance, and a greater AI (16.5% ± 0.25% 
versus 1.3% ± 0.2%, adjusted P = 0.046). Another interest-
ing finding of this study was that arterial compliance was 
impaired also in the subset of participants with white coat 
hypertension.51 Both sustained and white coat hypertensives 
showed a lower C1 and C2 compared with normotensive 
controls, without significant differences between the two 
hypertensive subgroups.
The above data indicate that, in young to middle-aged 
individuals, arterial distensibility assessment is helpful for 
identifying subjects at higher risk who may need early phar-
macological treatment. In these individuals, the measurement 
of central BP is a useful adjunct to clinical and 24-hour BP 
assessment, especially in subjects with ISH. As mentioned 
above, ISH individuals with low central BP have a lower 
risk of hypertension needing treatment than those with high 
central BP.22 However, the lack of reference values for the 
different arterial distensibility indexes in the young limits 
their applicability in clinical practice. Further prospective 
studies that relate arterial distensibility parameters to car-
diovascular events and mortality in young to middle-aged 
subjects are needed.
Hypertension and arterial stiffness 
in old age
Epidemiology has shown that the increase in BP with age 
begins from the very first weeks of life.51 Later, there is a 
progressive and graded increase of both systolic and dia-
stolic BP during adolescence and adult life, while after the 
age of 60–65 years, only the systolic component increases 
and the diastolic remains stable or even decreases. While 
diastolic values only increase until the age of 60–65 years, 
systolic values constantly increase, although with a different 
slope, progressively increasing PP. The arbitrary cutoff of 
140 mmHg is often exceeded, leading to a high prevalence 
of ISH in the elderly. The age-related BP increase during 
childhood and adolescence is mainly due to an increase in 
cardiac function and peripheral resistance, whereas during 
the rest of life it is due to progressive reduction of arterial 
compliance and to aortic calcification.51,52
A stiff aorta has increased impedance and does not 
dilate well under pressure, leading stroke volume to 
impact directly on the arterioles. This produces early 
arterial wave reflection. As a consequence, the reflected 
wave that falls within the diastolic phase of the cardiac 
cycle in young people, in the elderly tends to move into 
the systolic phase. This causes an increase in systolic BP 
and a parallel decrease in diastolic values. This process, 
involving the onset of sympathetic overactivity, is progres-
sive and very slow, and early wave reflection represents its 
final stage. Nevertheless, it should be pointed out that the 
increase in systolic BP with age is a general population 
phenomenon, not necessarily applicable to the individual 
subject. The “echogenetic context”53 is the reason why 
some subjects remain normotensive in advanced age. The 
phenotype “systolic BP” is the result not only of a mosaic 
of genes but also of a mosaic of environmental factors 
(Table 3).54–61
These factors, accounting for the wide variability of 
prevalence and incidence of hypertension around the world, 
act not only at the global level but also at a very local level. 
In the district of Lugalawa (Tanzania), subjects who are used 
to eating fish show a lower BP and no increase in systolic 
BP with increasing age in comparison with those of the 
same genetic strain living some kilometers away and eating 
a more complex diet.56 In Europe too, important differences 
were found in the prevalence of hypertension in a survey 
representative of the general population recruited from 
Table 3 Factors associated with unequal distribution of blood 
pressure levels
ethnic differences, genetics, and racial selectiona
Sodium intakeb (↑ intake leading to ↑ BP in genetically determined 
sodium-sensitive subjects)
intake of meat and vegetablesb (↑ meat/vegetable ratio leading to ↑ BP)
Social stressb (↓ stress leading to ↓ BP and to lack of ↑ BP with age)
Culturec (↓ culture leading to ↑ BP)
incomec (↓ income leading to ↑ BP)
industrialization (↑ industrialization leading to ↑ BP)
Altituded (↑ altitude leading to ↑ BP)
Temperature thermal excursiond,e (↑ temperature leading to ↑ BP)
water pollutionf (lead, cadmium)
Air particulateg (↑ particulate leading to ↑ BP)
Notes: aAgyemang et al90; bPavan et al59,60; cColhoun et al91; dHanna92; eAlpérovitch 
et al93; fSharp et al94; gSun et al.95
Abbreviation: BP, blood pressure.
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eight countries.62 Therefore, environmental factors play a 
role in allowing full expression of the genetic potential of 
individuals to become hypertensive with age, and the BP 
increase with age should be seen as a sort of adaptation to 
the environment.
Pulse pressure as a risk factor
After the age of 60–65 years, an increase in systolic BP with a 
decrease or no change in diastolic BP produces a progressive 
increase of PP.63,64 This increase, which was once considered 
nothing more than a normal characteristic of the elderly, is 
currently seen as a possible marker of endothelial dysfunction. 
PP is the simplest measure of large arterial stiffening and 
pulse hypertension, and is a better predictor of cardiovascular 
outcomes than systolic hypertension63,64 (Figure 3).
Darne et al were among the first researchers to dem-
onstrate that the pulsatile BP component is related to 
 cardiovascular outcome.65 However, their seminal results 
were difficult to interpret and impossible to implement in 
everyday clinical practice.65 First, calculation of the pulsatile 
and steady components required application of complex 
formulae obtained by use of principal component analy-
sis of data coming from just one population. Second, the 
physiologic meaning of the obtained indices was difficult 
to interpret.
Between 2000 and 2002, based on data from long-
standing epidemiologic studies and data obtained in the 
framework of large-scale clinical trials on hypertension, 
many researchers approached the question of whether PP 
(the physiologic pulsatile component of BP) or MAP, the 
(physiologic steady component of BP) is more closely related 
to cardiovascular outcome.
Blacher et al meta-analyzed individual patient data 
from three large-scale clinical trials, ie, EWPHE (European 
 Working Party on High Blood Pressure in the Elderly), 
Syst-Eur (Systolic Hypertension in Europe), and  Syst-China 
(Systolic Hypertension in China), all performed in elderly 
hypertensives.66 In this population of 7929 patients mostly 
affected with ISH, they were able to demonstrate that 
PP and not MAP is related to cardiovascular outcomes. 
A 10 mmHg wider PP, after adjustment for MAP and other 
possible confounders, was associated with a 15% (95% con-
fidence interval [CI] 7–22, P , 0.001) greater risk of total 
mortality, a 22% (95% CI 13–33, P , 0.001) greater risk 
of cardiovascular mortality, a 17% (95% CI 10–24) greater 
risk of fatal and nonfatal stroke, and a 13% (95% CI 2–24, 
P , 0.05) greater risk of fatal and nonfatal coronary events. 
MAP was not associated with an increase in risk for any of 
the studied outcomes.66
Staessen et al analyzed individual data for 15,693 patients 
aged 60 years or older with ISH who had been enrolled 
in eight clinical trials of hypertension, ie, SHEP (Systolic 
Hypertension in the Elderly Program), Syst-Eur, Syst-China, 
EWPHE, HEP (Hypertension Evaluation Project), STOP1 
(Swedish Trial in Old Patients with hypertension), MRC1 
(Medical Research Council trial of treatment of mild hyper-
tension), and MRC2 (Medical Research Council trial of 
treatment of hypertension in older adults).67 The principal aim 
of this analysis was to demonstrate that treatment of ISH in 
elderly patients with systolic BP $ 160 mmHg and diastolic 
BP , 95 mmHg reduces the incidence of cardiovascular 
complications. In an analysis stratified by level of PP at 
entry, in the subgroup with PP in the range of 65–89 mmHg, 
119 patients (95% CI 102–143) had to be treated for 5 years 
to prevent one death of cardiovascular origin, and 75 patients 
(95% CI 68–84) to prevent one coronary event, while the cor-
responding numbers in the subgroup with PP $ 90 mmHg 
were 63 (95% CI 58–70) and 57 (95% CI 53–62), for car-
diovascular mortality and coronary events, respectively.67 In 
an analysis restricted to 7757 patients who had been enrolled 
into the control groups of eight trials, 10 mmHg higher sys-
tolic BP was associated with 14% (95% CI 7–21) greater 
risk of all-cause mortality, while a 5 mmHg higher diastolic 
BP was associated with a 4% (95% CI 0–8) decrease in risk 
of all-cause mortality, thus stressing the role of PP as a risk 
factor for mortality (P = 0.05). Based on individual data for 
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Figure 3 Trend of 12-year cardiovascular (CV) mortality rate in relation to pulse 
pressure and systolic pressure.
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systolic pressure; the slope of pulse pressure is steeper and more linear than that 
of systolic pressure, that shows a J-shaped trend; data from 11,861 men and women 
aged 18–95 years from four italian general populations.54,55,61,62,64
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17,239 patients who were enrolled into control groups of 
seven randomized control trials (SHEP, Syst-Eur, MRC1, 
MRC2, HEP, EWPHE, STOP1), Ga˛sowski et al extended 
the results of the aforementioned analysis to patients of 
relatively younger age.68 The median age of the group was 
62.7 (range 26.3–97.0, 25% of patients ,50) years. Overall, 
a 10 mmHg wider PP at baseline was associated with a 6% 
(95% CI 3–10, P = 0.001) higher risk of all-cause mortality, 
a 7% (95% CI 1–13, P = 0.01) higher risk of cardiovascular 
mortality, and a 7% (95% CI 1–15, P = 0.03) higher risk of 
coronary mortality, but not with risk of fatal stroke. In similar 
analyses, MAP was not associated with risk of mortality. The 
PP-age interaction was significant for fatal stroke (P = 0.04). 
A 10 mmHg wider PP was associated with a 29% lower risk 
of fatal stroke in patients aged ,56 years, a 13% higher risk 
of fatal stroke in patients aged 56–68 years, and a 16% higher 
risk of fatal stroke in patients aged .68 years. The interaction 
between MAP and age was significant for fatal coronary heart 
disease (P = 0.01). A 5 mmHg higher MAP was associated 
with a 10% higher risk of fatal coronary disease in patients 
aged ,56 years, an 8% higher risk of coronary disease in 
patients aged 56–68 years, and a 3% lower risk of fatal coro-
nary disease in those aged .68 years.68
PP is related to adverse cardiovascular outcome indepen-
dent of other BP components. Although this is especially true 
of older patients with ISH, the relationship, in the case of 
fatal outcomes, seems to hold true in populations where large 
proportions of patients are ,50 years, although for some 
outcomes, MAP gains predictive significance at younger 
ages. The role of PP is not limited to classic cardiovascular 
outcomes. It has been demonstrated, that in pregnant women 
with hypertension developing in the third trimester, 24-hour 
ambulatory PP is an independent predictor of preterm 
delivery and small body weight at birth.69 Widening PP may 
therefore be more predictive of cardiac risk than either sys-
tolic or diastolic BP considered separately. Therefore, it has 
been proposed that high PP might be part of the Framingham 
cardiovascular risk score.70
Relationship between sympathetic 
nervous system activity and arterial 
function
There is growing evidence that both sympathetic 
overactivity71,72 and arterial stiffening73 are implicated in 
the development of hypertension and its complications. 
Increased adrenergic activity in patients with hypertension 
is supported by various lines of evidence, including mea-
surements of heart rate and catecholamine levels, and data 
obtained using microneurography. Potential mechanisms 
leading to increased sympathetic activity in hypertension 
may be divided into two major categories, ie, increased 
adrenergic activity resulting from disturbed peripheral 
regulatory mechanisms such as arterial baroreceptors, 
cardiopulmonary  mechanoreceptors, and chemoreceptors, 
and a primary increase of sympathetic activity within the 
central nervous system. These  abnormal mechanisms, either 
peripheral or central, are likely related to both genetic and 
environmental factors. Studies using regional catecholamine 
spillover techniques showed increased noradrenaline release 
in the central nervous system in patients with hypertension.74 
This involved mainly subcortical regions, such as those 
responsible for emotional responses. The sympathetic 
 nervous system may thus constitute an important link 
between mental stress and hypertension. This concept is 
based on the following  findings: persistent sympathetic 
nervous stimulation is commonly present in hypertensives; 
suprabulbar projections of noradrenergic brainstem neurons 
are activated; and adrenaline is released as a cotransmitter in 
sympathetic nerves. With a better understanding of the role 
of the sympathetic nervous system, a rational background 
for more effective treatment of hypertension and better 
prevention of cardiovascular events has been established. 
Of note, adrenergic activation is a hallmark of not only 
hypertension, but also metabolic syndrome, obstructive sleep 
apnea, congestive heart failure, and chronic kidney disease. 
Thus, it appears that activation of the adrenergic system may 
be a common pathogenetic mechanism in these conditions.
The level of sympathetic nervous activity may determine 
properties of large arteries. Removal of adrenergic tone by 
anesthesia of the brachial plexus and the spinal cord results 
in markedly increased distensibility of the radial artery 
and femoral artery, respectively.75 Short-term sympathetic 
activation is able to decrease radial arterial compliance. 
The reduction in arterial compliance probably results from 
complex interactions between changes in distending BP and 
changes in radial arterial smooth muscle tone. Interestingly, 
pathological states characterized by sympathetic nervous 
system activation (congestive heart failure, renal failure, and 
obstructive sleep apnea) are associated with artery stiffness. 
Furthermore, cigarette smoking, which has a powerful 
sympathetic excitatory effect, is associated with impairment 
of large artery function and increased aortic stiffness.76 
These changes are reversible with smoking cessation. 
Finally, there is growing evidence that tachycardia, a reliable 
marker of high sympathetic tone and cardiovascular risk,77 
is an important determinant of arterial function and PWV.23 
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Swierblewska et al have recently shown that sympathetic 
activity is an  independent determinant of PWV and diastolic 
function in normal humans.78 Data from HARVEST are in 
agreement with those results.79 In the participants divided 
according to whether they had sympathetic predominance 
or normal autonomic nervous system activity, assessed by 
spectral analysis of heart rate variability performed in the 
lying position, on standing or during a mental stress,  subjects 
with sympathetic predominance exhibited impaired C1 
and C2 compared with subjects with normal activity of the 
autonomic nervous system.79 The link between autonomic 
nervous system activity and arterial stiffness might reflect a 
direct effect of sympathetic discharge on vasomotor tone.80,81 
However, other mechanisms might be implicated. First, the 
sympathetic nervous system promotes endothelial dysfunc-
tion, growth of vascular muscle and associated fibrosis, ie, 
structural changes of the arterial wall, playing a role per 
se in the increase in arterial stiffness, independently of BP. 
Second, the sympathetic nervous system may contribute 
to arterial stiffness by its effects on the renin-angiotensin 
aldosterone system, promoting arterial wall fibrosis. Third, 
increased sympathetic activity and consequent loss of large 
vessel elasticity might facilitate transmission of pressor stress 
into the resistant vessels and microvasculature. In addition, 
resetting of the baroreflex by both sympathetic overactivity 
and structural changes might further facilitate target organ 
damage.
In conclusion, sympathetic overactivity is implicated in 
the stiffening of large arteries and diastolic dysfunction, and 
thereby might contribute to development and progression 
of hypertension and its complications. Along with more 
standard measures, such as heart rate and BP, sympathetic 
activity should also be taken into account in interpreting and 
understanding measures of arterial function.
Interactive effect of genetics and 
salt intake on arterial properties
Another important determinant of the properties of the elas-
tic arteries is salt intake. As mentioned above, hypertension 
arises through the complex interaction between genetic, 
environmental, and lifestyle factors. More than 150 candidate 
genes have been studied in relation to hypertension and other 
cardiovascular phenotypes.82 Often, strong associations are 
reported that are not confirmed in subsequent studies.  However, 
a negative finding or a minor genetic effect in a general popu-
lation may become a major genetic effect in the presence of 
a particular environmental background. This relationship 
has been explored within the frame of EPOGH, a European 
family-based epidemiological survey.83 The aim of EPOGH is 
to investigate the interactions between genes and environment 
in the pathogenesis of hypertension and related intermediate 
phenotypes, focusing on the relationship between genes 
encoding various components of the renin- angiotensin-
aldosterone system and the adducin cytoskeleton, and sodium 
excretion as an index of salt intake. The hypothesis of effect 
modification of the aforementioned genes by sodium intake 
was made a priori because renin-angiotensin-aldosterone 
system and adducin play a key role in sodium homeostasis 
and, via various mechanisms, high sodium might affect BP 
and sympathetic tone, promote  cardiac growth and change 
wall properties of the large arteries. Angiotensin II and aldos-
terone generated by the angiotensin-converting enzyme and 
aldosterone synthase, respectively, not only regulate sodium 
and water homeostasis, but also influence vascular remodeling 
in response to high BP. In 622 EPOGH subjects from three 
European populations, Wojciechowska et al investigated 
whether the angiotensin-converting enzyme D/I and cyto-
chrome P450 (CYP)11B2 C-344T polymorphisms influence 
arterial wave reflections, a measure of vascular stiffness.83 
The peripheral and central AIs were significantly higher 
in CYP11B2-344C allele carriers than in CYP11B2-344T 
homozygotes in population-based and family-based analyses. 
However, this effect of the CYP11B2 polymorphism only 
occurred in subjects with a higher than median urinary sodium 
excretion (210 mmol/day). The association between systolic 
augmentation and the angiotensin-converting enzyme D/I 
polymorphism did not reach statistical significance.83 Previous 
studies demonstrated that a high salt intake in humans is 
associated with increased arterial stiffness and vascular hyper-
trophy.84 Furthermore, stroke-prone spontaneously hyperten-
sive rats fed 0.9% NaCl in drinking water, compared with a 
control group given tap water, had increased expression of 
mRNA for CYP11B2 in the arterial wall, but lower levels of 
circulating aldosterone.85 Thus, an excessive salt intake might 
contribute to increased arterial stiffness by inappropriately 
sustaining expression of the CYP11B2 gene in the arterial 
wall, especially in CYP11B2-344C allele carriers. Adducin is 
a membrane skeleton protein consisting of α- and β- or α- and 
γ-subunits. Mutations in α- and β-adducin are associated with 
hypertension. In the framework of the EPOGH study, Cwynar 
et al investigated whether polymorphisms in the genes encoding 
α-adducin (Gly460Trp), β-adducin (C1797T), and γ-adducin 
(A386G), alone or in combination, affected PP, an index of 
vascular stiffness.86 Peripheral and central PP were measured 
by conventional sphygmomanometry and applanation 
tonometry, respectively. Among carriers of the α-adducin 
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Trp allele, peripheral and central PP were 5.8 and 4.7 mmHg 
higher, respectively, in γ-adducin GG homozygotes than in 
their AA counterparts, due to an increase in systolic pressure. 
γ-adducin GG homozygosity was associated with a lower 
urinary Na+/K+ ratio among α-adducin Trp allele carriers and 
with a higher urinary aldosterone excretion among α-adducin 
GlyGly homozygotes. Sensitivity analyses in founders and 
offspring separately, and tests based on the transmission of 
the γ-adducin G allele across families, confirmed interac-
tion between the α-adducin and γ-adducin genes.86 Previous 
observations demonstrated that, in the population at large, the 
plasma concentration of endogenous ouabain, a steroid hor-
mone released from the adrenal gland and possibly from the 
hypothalamus, increases with the number of mutated α-adducin 
Trp alleles.87 At very low concentrations within the nanomolar 
range, endogenous ouabain may enlarge the membrane pool of 
active sodium pumps and activate mediators of cell growth.87 
To what extent the aforementioned pathways might increase PP, 
either via renally mediated effects on circulating plasma volume 
and cardiac output, or via structural or functional alterations in 
the vasculature, must be further clarified. The EPOGH dem-
onstrated that individuals with the same genetic predisposition 
had different vascular stiffness depending on whether they ate 
a high-sodium or a low-sodium diet. As demonstrated by the 
present results, environmental factors modify the actions of 
genes. Thus, population studies that take into account gene-
environment and gene–gene interactions will increasingly be 
used to study complex cardiovascular phenotypes.
Conclusion
Arterial stiffness is a well recognized predictor of car-
diovascular morbidity and mortality. However, the large 
number of parameters used to define arterial stiffness and 
the differing modalities used to assess aortic mechanics 
have somewhat hampered the current clinical impact of 
these measures. Carotid-femoral PWV is the most validated 
method used to quantify arterial stiffness noninvasively and 
is considered today the gold standard index, given its strong 
prediction of cardiovascular events and mortality. The AI 
and central BP reflect different facets of the pathophysi-
ological abnormalities underlying functional vascular dam-
age because both central arterial stiffness and peripheral 
reflectance are important determinants of these parameters. 
The main problem with these derived parameters is cal-
culation by means of a transfer function, which has only 
been validated in selected patient groups. In addition, the 
independent predictive value of central hemodynamics in 
primary prevention remains to be determined. It has been 
hypothesized that the high prognostic predictive value of 
PWV could be due to its reflecting the cumulative damage 
of cardiovascular risk factors on the arterial wall over long 
periods, whereas central hemodynamics can fluctuate over 
time, and a sporadic measurement may not reflect their 
long-term impact on the arterial wall. On the other hand, 
each of the above mentioned parameters reflects a differ-
ent characteristic of the atherosclerotic process, involving 
functional and/or morphological changes in the vessel wall. 
Therefore, acquiring simultaneous measurements of dif-
ferent parameters of vascular function and structure could 
theoretically enhance the power to improve risk stratifica-
tion. According to McEniery et al, the AI might be a more 
sensitive marker of arterial alteration and cardiovascular risk 
in younger individuals, whereas the aortic PWV is likely to 
be a better measure in older individuals.88 However, whether 
pulse wave analysis can equally predict different end-organ 
damage has to be elucidated. Further studies are needed to 
compare the usefulness of each of these parameters among 
different populations of subjects with differing clinical 
characteristics.
Since the pioneering and revolutionary approach of 
Strus´ to measurement of the pulse, many conceptual and 
technical achievements have been obtained in the area of 
arterial hemodynamics. Continuous technological effort is 
necessary to refine our methods of investigation in order to 
detect early arterial abnormalities. Arterial stiffness and its 
consequences represent the great challenge of the twenty-
first century for affluent countries, and “de-stiffening” will 
be the goal of the next decades. As demonstrated by a num-
ber of controlled trials, the separate reduction of systolic 
and diastolic BP is able to reduce major cardiovascular 
events significantly, not only in the elderly but also in the 
very old.89 However, it is possible that an excess reduction 
of diastolic BP accounts for the not completely satisfactory 
results sometimes observed with antihypertensive treat-
ment, particularly on coronary mortality. Unfortunately, 
selective reduction of systolic rather than diastolic BP is 
a difficult target. Lifestyle measures reproducing the con-
ditions spontaneously present in emergent countries, such 
as healthy diet, increase of physical activity, and reduction 
of stress, should be taken into consideration as possible 
destiffening measures in addition to drugs.
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